We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Recent discussions among investors regarding Hvivo Plc (HVO) indicated a notable level of concern regarding future share price performance, specifically amidst the anticipation of upcoming contracts. Participants expressed anxiety about the potential decline in stock value should no significant contracts be finalized before the deadline of April 10th. One investor, chica1, stated, "Mo needs to get contracts over the line. If there's nothing before April 10th, Hvivo will take another leg DOWN!!!" This sentiment reflects a general unease about the company's ability to secure new business.
Financial highlights from the discussions point to critical movements in director shareholdings, particularly the recent sale of shares by the chairman, which has raised eyebrows among investors. Comments from sikhthetech highlighted this issue, stating, "HVO chairman dumped his entire holding 28p/29p," which has led to speculation about the company's stability and future direction. Investors are seemingly awaiting the upcoming announcement of annual results and the accompanying presentation by the CEO and CFO as pivotal moment for HVO, with many emphasizing the importance of company news flow in shaping investor sentiment. As suggested by burtond1, the April 10th RNS regarding annual results will be closely monitored, with implied expectations that it could either stabilize or further destabilize stock performance.
Show more
hVIVO Plc, a leading Contract Research Organisation specializing in human challenge clinical trials, has recently reported significant developments impacting its leadership and financial outlook. On March 26, 2025, it was disclosed that Martin Gouldstone, the Non-Executive Director of hVIVO, also serving as CEO of Oncimmune Holdings plc, faced administrative action as Oncimmune was placed into administration. This situation may raise questions regarding the governance and leadership of hVIVO in the context of the challenges its board members are facing.
In addition, hVIVO has announced that it will release its financial results for the year ending December 31, 2024, on April 10, 2025. The company is set to hold an analyst briefing and a live presentation for investors led by CEO Yamin 'Mo' Khan and CFO Stephen Pinkerton on the same day. These upcoming results and presentations are critical for stakeholders as they assess hVIVO’s performance and strategic direction moving forward. As a fast-growing entity in the CRO sector, the company's upcoming disclosures will likely be closely scrutinized by analysts and investors alike, given the recent developments concerning the company's leadership.
Show more
in other words please sell i want a better buying price . seen it all before freil sold at 28p 3 weeks later it was 30.6p if he did not sell he would this year have been taxed to the hilt under the disaster they call labour . instis still buying are you telling me a major share holder does not speak to the company f me lol |
There is no doubt whatsoever that Cathal would have had better knowledge of HVO than any research Octopus could have carried out. Cathal dumped his entire holding just under 30p Octopus are averaging down with a 40 percent loss with share price sitting at 17p.I dread ro think where the share price would be if it wasn't for Octopus. It's quite frightening actually. A poor T/U in February and this share price is going to tank even further. Mo really needs to pull something special out of the bag here. |
Agreed there is a question mark over the quality of Octopus managers--Titan vct fund has been a disaster over the past couple of years |
Pogue |
Long HVO for a quick bounce at 17.1p |
Big chunk gone through today- see if its enough to turn the ship around... |
Pogue |
I should have put “bargain” |
GregB |
Imagine where the share price would be if Octopus weren't buying. Sub 10p probably. |
Phew!! Thank goodness Octopus are still buying and not offloading. |
HVO the gift that keeps on giving. A traders dream. I can't wait until February when this share price drops to 12p. Octopus must be furious while Cathal is laughing his head off. |
Where's 1gw and his mates?? |
LFDKMP |
Not sure it was a bargain at 30p to be honest. Looking quite miserable at the moment. Sentiment is rock bottom. Long term holders of HVO and POLB must be kicking themselves for not cashing last summer. |
Well its now twice the bargain it was at 30p. |
My thoughts exactly, 2024 in the bag and 2025 only 13 days in. Surely no one spends millions moving premises with greater capacity for no reason. |
As I predicted then. |
It's been atrociously managed by Mo...... |
Visibility and sentiment. |
No one seems to be taking the update in the 10th December RNS at face value. What do you think has changed in the last month? Is the perception now that the outlook for 2025 is going to be significantly worse than the 2024 figures? |
It's been a brutal selloff. |
So about 6 months behind the timeline, I wonder if the client is still onboard? There has been a lot of news about hMPV recently... |
I'm sorry but the first news of 2025 needed to be a contract. |
hVIVO successfully completes pilot characterisation study for hMPV, prepares for challenge trialshttps://youtu. |
Type | Ordinary Share |
Share ISIN | GB00B9275X97 |
Sector | Pharmaceutical Preparations |
Bid Price | 14.00 |
Offer Price | 14.50 |
Open | 14.75 |
Shares Traded | 2,420,608 |
Last Trade | 16:35:04 |
Low - High | 14.25 - 14.75 |
Turnover | 56.04M |
Profit | 16.12M |
EPS - Basic | 0.0237 |
PE Ratio | 6.01 |
Market Cap | 100.35M |
Pivozon’s expert advisor enhances gold trading with smart, long-term strategies and precise, data-driven entries. Leading developer of algorithmic forex trading solutions Avenix Fzco has launched Pivozon, an advanced expert advisor (EA) designed to enhance gold trading (XAU/USD). The product integrates sophisticated technical indica...
Continue Reading
Concerns are mounting among U.S. lawmakers over the potential risks posed by President Trump’s involvement in cryptocurrency and Elon Musk’s growing influence. They argue that these factors could destabilize the financial system, undermine regulatory oversight, and diminish public confidence in government accountability. As th...
Continue Reading
London stocks on the FTSE 100 were little changed in early trade on Friday as investors mulled the latest UK GDP and retail sales figures, and continued to assess the impact of Trump’s auto tariffs. At 0830 GMT, the FTSE 100 was steady at 8,664.48. Kathleen Brooks, research director at XTB, said: “It will be an […]
Continue Reading
An action has been prompted against the moves exhibited by bulls slightly breaking through the line of 65 in recent times in the exchanges of Ecora Resources Plc (LSE:ECOR), given that the stock market now holds downward to the tune of around 60.5 or thereabouts, attempting a re-base possibly around the points of 60. The […]
Continue Reading
FxSpire, a cutting-edge automated trading solution, uses AI to detect false breakouts in EUR/USD trading, boosting accuracy. FxSpire has unveiled its latest innovation to aid forex traders: an advanced false-breakout detection algorithm which enhances the accuracy of EUR/USD trading, running on the MetaTrader4 platform. This new technolog...
Continue Reading
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions